Lucid’s Medicare Win and $15M Capital Raise: A Big Step but Still a Risky Stock
Lucid Group’s Medicare win for EsoGuard® sparks hope, but a $15 M capital raise and weak share price hint that the company still faces big execution risks.
3 minutes to read